SCHEMBL3369050

SCHEMBL3369050

Clc1ccccc1OP(Cl)Cl.O=P(Cl)(Cl)Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PTK2B Q14289 1/20 0.39
HPGD P15428 4/20 0.37
TSHR P16473 3/20 0.36
MAPK1 P28482 1/20 0.36
PKM P14618 2/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CXCL8 P10145 1/20 0.35
RAB9A P51151 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ALDH1A1 P00352 2/20 0.34
HDAC6 Q9UBN7 1/20 0.34
NPC1 O15118 1/20 0.34
STAT3 P40763 1/20 0.34
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7602939 0.89 LMNA (0.43) LMNASMN1; SMN2HPGDTSHRPKM
SCHEMBL5503597 0.73 LMNA (0.45) LMNASMN1; SMN2HPGDTSHRPKM
SCHEMBL29482311 0.72 LMNA (0.67) LMNASMN1; SMN2PTK2BHPGDTSHR
SCHEMBL30657703 0.72 LMNA (0.67) LMNASMN1; SMN2PTK2BHPGDTSHR
SCHEMBL7600529 0.72 LMNA (0.41) LMNASMN1; SMN2PTK2BHPGDTSHR
SCHEMBL1070126 0.72 LMNA (0.67) LMNASMN1; SMN2PTK2BHPGDTSHR
SCHEMBL1377760 0.72 LMNA (0.67) LMNASMN1; SMN2PTK2BHPGDTSHR
SCHEMBL11553081 0.72 LMNA (0.43) LMNASMN1; SMN2HPGDTSHRPKM
SCHEMBL11677163 0.72 LMNA (0.43) LMNASMN1; SMN2HPGDTSHRPKM
SCHEMBL2035293 0.70 LMNA (0.69) LMNASMN1; SMN2PTK2BHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS, INC. 2017-07-27 US disclosed
US-9637515-B2 Guggulphospholipid methods and compositions JINA PHARMACEUTICALS, INC. (US) 2017-05-02 US disclosed
EP-2088865-B1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2015-10-21 EP disclosed
US-20100151002-A1 Guggulphospholipid Methods and Compositions JINA PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed
EP-2088865-A2 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS Jina Pharmaceuticals Inc. (US) 2009-08-19 EP disclosed
WO-2008058156-A9 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2008-12-04 WO disclosed
WO-2008058156-A2 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC. (US) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151002-A1 Guggulphospholipid Methods and Compositions SGMS2, SGMS1, PLA2G5 LMNA 1323/4885SMN1; SMN2 3094/4885PTK2B 4549/4885
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS SGMS1, SGMS2, GGPS1 LMNA 1667/4885SMN1; SMN2 3304/4885PTK2B 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.